Summary (tl;dr)

A nationwide recall has been issued for thousands of bottles of chlorthalidone, a common blood pressure medication, because the tablets may not dissolve correctly, potentially making them less effective at controlling blood pressure.

Essential Background

Chlorthalidone is a diuretic, commonly referred to as a "water pill," prescribed to treat high blood pressure and reduce fluid retention linked to conditions like heart failure, kidney disease, or liver disease. Its mechanism involves assisting the kidneys in removing excess water and salt from the body. For the medication to be effective, proper dissolution of the tablet is critical, as it ensures the active ingredient is absorbed correctly and delivers the intended dosage. If a tablet does not dissolve as expected, the body may not receive the medicine in the intended way, potentially leading to uncontrolled blood pressure.

The Full Story

Inventia Healthcare Limited, an India-based pharmaceutical company, initiated a recall of specific lots of Chlorthalidone Tablets, USP, 25 mg, on September 3, 2026, because the product failed dissolution specifications. The U.S. Food and Drug Administration (FDA) subsequently classified this as a Class II recall on September 17, 2026. This classification indicates that while the probability of serious health consequences is remote, use of the product may cause temporary or medically reversible adverse health consequences. Approximately 13,567 bottles, each containing 100 tablets, were distributed nationwide and are affected by this recall. This is the second recall this year for chlorthalidone tablets from Inventia Healthcare Limited due to dissolution issues, following a similar recall in June that involved over 11,000 bottles. Rising Pharma Holdings Inc. of New Jersey was the U.S. distributor for the recalled chlorthalidone tablets.

Why It Matters

This recall is significant because if the chlorthalidone tablets do not dissolve correctly, patients may not receive the full therapeutic dose of the medication, thereby reducing its effectiveness in managing high blood pressure. For individuals who rely on this medication to control their blood pressure, a decrease in efficacy could elevate their risk of serious health issues over time, such as heart attack, stroke, or kidney damage. While the FDA's Class II designation suggests a low risk of severe harm, healthcare professionals strongly advise patients not to discontinue their medication abruptly without first consulting their doctor, as stopping blood pressure medication suddenly can lead to dangerous health complications. Patients are encouraged to check the lot number on their medication bottle and contact their healthcare provider or pharmacist if their prescription is part of the recall.

Geographic Location

• United States (nationwide distribution of recalled medication)
• India (Inventia Healthcare Limited, manufacturer of recalled medication)
• New Jersey, United States (Rising Pharma Holdings Inc., U.S. distributor)